Pharmaceutical Research, Vol. 24, No. 5, May 2007 ( # 2007)
DOI: 10.1007/s11095-006-9211-2
Research Paper
Raman Chemical Imaging for Ingredient-specific Particle Size Characterization
of Aqueous Suspension Nasal Spray Formulations: A Progress Report
William H. Doub,1,4,5 Wallace P. Adams,2 John A Spencer,1 Lucinda F. Buhse,1 Matthew P. Nelson,3
and Patrick J. Treado3
Received September 12, 2006; accepted December 8, 2006; published online March 20, 2007
Purpose. This study was conducted to evaluate the feasibility of using Raman chemical imaging (i.e.,
Raman imaging microspectroscopy) to establish chemical identity, particle size and particle size
distribution (PSD) for a representative corticosteroid in aqueous nasal spray suspension formulations.
Materials and Methods. The Raman imaging PSD protocol was validated using polystyrene (PS)
microsphere size standards (NIST-traceable). A Raman spectral library was developed for the active and
inactive compounds in the formulation. Four nasal sprays formulated with beclomethasone dipropionate
(BDP) ranging in size from 1.4 to 8.3 mm were imaged by both Raman and brightfield techniques. The
Raman images were then processed to calculate the PSD for each formulation.
Results. Within each region examined, active pharmaceutical ingredient (API) particles are unambiguously identified and the total number of those particles, particle size and PSD of API free of excipients
and PSD of API particles adhered to other excipients are reported.
Conclusions. Good statistical agreement is obtained between the reported and measured sizes of the PS
microspheres. BDP particles were clearly distinguishable from those of excipients. Raman chemical
imaging (RCI) is able to differentiate between and identify the chemical makeup of multiple
components in complex BDP sample and placebo mixtures. The Raman chemical imaging method
(coupled Raman and optical imaging) shows promise as a method for characterizing particle size and
shape of corticosteroid in aqueous nasal spray suspension formulations. However, rigorous validation of
RCI for PSD analysis is incomplete and requires additional research effort. Some specific areas of
concern are discussed.
KEY WORDS: drug delivery; nasal; image analysis; spectroscopy; Raman.
INTRODUCTION
Nasal delivery of drug products is becoming increasingly
common due to the potential for increased drug uptake rates,
improved bioavailability for certain drugs relative to oral
This article represents the personal opinions of the authors and does
not necessarily represent the views or policies of the US Food and
Drug Administration.
1
Division of Pharmaceutical Analysis, Food and Drug Administration/CDER/OPS, St. Louis, Missouri, USA.
2
Office of Generic Drugs, Food and Drug Administration/CDER/
OPS, Rockville, Maryland, USA.
3
ChemImage Corporation, 7301 Penn Avenue, Pittsburgh, Pennsylvania 15208, USA.
4
Division of Pharmaceutical Analysis, Food and Drug Administration, 1114 Market St., St Louis, Missouri 63101, USA.
5
To whom correspondence should be addressed. (e-mail: william.
doub@fda.hhs.gov)
ABBREVIATIONS: API, active pharmaceutical ingredient; BDP,
beclomethasone dipropionate; FOV, field-of-view; MCC, microcrystalline cellulose; NIST, National Institute of Standards and Technology;
PS, polystyrene; PSD, particle size distribution; LLS, laser light scattering; RCI, Raman chemical imaging.
0724-8741/07/0500-0934/0 # 2007 Springer Science + Business Media, LLC
dosing, and the convenience of nasal delivery. When
conducting product quality studies in support of new drug
applications (NDAs) or abbreviated new drug applications
(ANDAs), it is relatively straightforward to determine
pharmaceutical equivalence of nasal spray products, whereby
products are considered pharmaceutical equivalents if they
contain the same API(s), are of the same dosage form, route
of administration and are identical in strength or concentration. In contrast, assessment of bioequivalence (BE) of nasal
drug delivery products is much more challenging.
The approach of the FDA for establishing BE for
solution formulations of locally acting nasal sprays and
aerosols is to rely on in vitro methods, based on the
assumption that in vitro studies would be more sensitive
indicators of drug delivery to nasal sites of action than would
be clinical studies (1). However, the present recommended
approach for establishing BE of suspension formulations of
locally acting nasal drug products, both sprays and aerosols,
is to conduct in vivo studies, despite being time consuming,
costly and often inconclusive, in addition to in vitro studies.
In vivo studies are recommended because of the lack of a
validated method for characterizing API-specific drug particle size and particle size distribution (PSD) in nasal aerosols
and sprays.
934
Raman Imaging of Aqueous Nasal Spray Suspensions
Although drug particle size distribution (PSD) can be
readily determined by a number of methods prior to
formulation into a finished product, the primary challenge
has been to determine the PSD of the drug substance in the
finished nasal aqueous suspension products in the presence of
undissolved excipients. Nasal spray suspension formulations
typically contain, in addition to the API, suspended microcrystalline cellulose and a number of dissolved excipients,
which may include carboxymethylcellulose sodium, polysorbate 80, benzalkonium chloride, edetate disodium, phenylethyl alcohol, dextrose and other ingredients. Excipients such
as microcrystalline cellulose typically have a median particle
size that is larger than the API. However, excipients often
exhibit a broad PSD and a substantial number of excipient
particles may exist in the same size range as the drug
substance, thus complicating drug substance particle size
determination.
To address the limitations of existing PSD methods to
support in vitro BE studies, a methodology for ingredientspecific PSD determination based on Raman chemical
imaging (RCI) technology was investigated. Availability of
such a method would equip pharmaceutical scientists with an
in vitro assessment method that will more reliably determine
API-specific PSD of drug substances in finished drug
products.
In this paper, we investigate the use of RCI (2Y6) in
conjunction with brightfield reflectance imaging to measure
chemical identity, particle size, PSDs, and particle associations of corticosteroids in an aqueous nasal spray suspension
product. Briefly, RCI, a method combining the capabilities of
molecular spectroscopy and advanced digital imaging, enables users to detail material morphology and composition
with a high degree of specificity in a non-contact, nondestructive manner. An advantage of using Raman chemical
imaging is that each pixel in an image has an associated
Raman spectrum. Interrogation of individual pixels assists in
the interpretation of the data. Presence or absence of API
within individual particles can be determined by whether or
not the Raman spectral features characteristic of the drug are
present.
In the widefield chemical imaging approach used in this
work, in which widefield refers to laser illumination of the
entire field of view defined by the microscope objective, digital
images are acquired at defined Raman scattered spectral
features, by imaging multiple sample particles through an
electro-optically tunable filter imaging spectrometer. The
Raman chemical imaging microscope simultaneously provides
diffraction-limited spatial resolution (approaching 250 nm for
high signal-to-noise images) and high Raman spectral resolution (<9 cmj1). Alternative Raman imaging technologies
based on point mapping (7Y11) and line scanning (12,13) are
not able to achieve comparable spatial/spectral resolution
performance. The no-moving-parts approach employed to
construct Raman images enables fusion of optical and
Raman chemical imaging data. Fused optical/Raman images
are used to guide the differentiation between drug aggregates
and individual particles. Validation of the optical/Raman
imaging fusion methodology has been performed by
characterizing a set of NIST-traceable polystyrene microsphere size standards.
935
MATERIALS AND METHODS
Materials
Beclomethasone Dipropionate (BDP) aqueous nasal
spray was chosen as the focus of this study as it is a commonly used high-dose nasal spray suspension product. A
commercial product, Beconase AQ (GSK), was used for
initial imaging experiments by brightfield reflectance, polarized light, and Raman techniques. The API, BDP, was
supplied by SICOR, S.p.A. (Milan, Italy) as six micronized
API samples having volume median particle diameters of 1.4
(lot D), 1.8 (lot E), 2.2 (lot F), 3.4 (lot H, repeated as a
blinded duplicate), 8.3 (lot I), and 1.8 (lot J) mm determined
at SICOR using laser light scattering (LLS). The particle
sizes were blinded to the ChemImage personnel. In addition
to API, pure excipient components were examined so as to
obtain pure component signature Raman spectra. The
inactive components included: microcrystalline cellulose
(MCC, Avicel, lot 2130) obtained from FMC Corporation;
carboxymethylcellulose sodium (CMC) obtained from KV
Pharmaceuticals; dextrose (lot A16A) obtained from Kodak
Chemicals; benzalkonium chloride (MCB brand) as a 50% by
weight aqueous solution obtained from EM Science; polysorbate 80 (lot 742504) obtained from Fisher Scientific; and
phenylethyl alcohol (lot 118PF3435) obtained from SigmaAldrich. For validation of the Raman chemical imaging PSD
protocol, six NIST-traceable polystyrene (PS) microsphere
size standards having mean particle diameters of 0.71, 1.0,
2.1, 5.1, 10 and 32 mm were obtained from Duke Scientific
(Duke). Particle size for the smallest particles (0.71 mm) was
determined by Duke using transmission electron microscopy.
The particle size for all other particles was determined using
optical microscopy. Demonstration of RCI PSD analysis was
performed on five formulated BDP nasal spray samples.
Formulations were prepared at FDA_s Division of Pharmaceutical Analysis according to a commercial formulation
containing the six excipients indicated above for Beconase
AQ. The BDP formulations were provided in spray pump
bottles as blinded samples to minimize bias.
Nasal Spray Particulate Preparation
Samples were prepared by shaking, priming (four
actuations each) and spraying each nasal spray sample in an
upright position onto inverted aluminum-coated glass microscope slides positioned approximately 15 cm from the spray
nozzle. The samples were then immediately turned upright
and allowed to dry. Aluminum-coated glass microscope slides
were used to reduce background response of the detection
substrates, including minimizing Raman scatter and background fluorescence typically observed from uncoated glass
microscope slides.
Instrumentation
Particle size and particle size distribution measurements
were carried out on the API using a BeckmanYCoulter
LS100Q laser particle size analyzer equipped with a microvolume accessory. The powder in liquid method was used
Doub et al.
936
with 0.2% Tween 80 (v/v) in water as the suspending agent
for obscuration values between 8 and 12% with the stirrer set
at 50%. Suspensions were sonicated for 15 min. A 60-s
background was collected and data were analyzed according
to the Mie model.
Raman spectra, brightfield images, polarized light images and Raman chemical images were obtained using a
FALCONi Raman Chemical Imaging microscope (ChemImage Corporation, Pittsburgh, PA). Raman scattering was
achieved by delivering up to 160 mW of 532 nm laser
excitation power through a 50X microscope objective to
generate a laser spot diameter of 50 mm and a power density
of 8.2103 W/cm2 at the sample. Raman chemical images
were collected over an API-specific Raman spectral region at
approximately 9 cmj1 increments with an average 40 s
integration time per image frame. The time required to
image a single sample varied depending on the number of
sampled FOVs, the integration time per image frame and
the total number of image frames. For example, a data set
consisting of 50 FOVs at a rate of 40 s per frame for a total of
300 image frames would take approximately 3 h and 20 min to
collect. For the formulated nasal spray samples, Raman
chemical images were collected and analyzed until at least
100 API particles were counted. To achieve this, surface areas
covered for each sample ranged from 39,800 mm2 (õ200
mm200 mm) to 826,875 mm2 (õ900 mm900 mm) per
sample. Using 22 camera binning to enhance image signal
to noise ratio, the Raman chemical images exhibited neardiffraction-limited resolution of õ0.3 mm/pixel. The
microscope system was calibrated using a 1951 USAF
resolution target. The total number of spectra generated
for each of the formulated drug samples ranged from 442,225
to 9,187,000. Images were analyzed using ChemImage
Xperti software.
Detection Protocol
In order to assess the API-specific size distribution in
nasal spray product formulations, a systematic methodology
was developed.
Step 1. Collect and analyze Raman spectra of pure
ingredients. A dispersive Raman spectral library was collected
for all active and inactive components in the nasal spray
product. This analysis was conducted to determine the optimal
spectral range to be used during the Raman chemical imaging
analysis so as to discriminate the API from other ingredients in
the formulation. The spectral range of 1,630Y1,700 cmj1 was
selected on the basis of highest API-specific Raman signal to
excipient background ratio. The 1,662 cmj1C=C stretching
mode of BDP provided the best API to excipient
discrimination.
Step 2. Demonstrate Raman chemical imaging PSD
analysis on pure micronized drug substance whose PSD was
blinded to the analysts. Raman chemical imaging was
performed by ChemImage personnel on six lots of drug
substance provided as blinded samples by FDA personnel.
Each sample was prepared by spreading a small amount of
micronized BDP on a glass microscope slide to form a
monolayer of particles. For each sample, three regions of
interest were imaged using brightfield microscopy, polarized
light microscopy and Raman chemical imaging. Raman
chemical images of the 1,662 cmj1 spectral feature were
collected and processed to produce a binary Raman image to
which an automated particle sizing routine could be applied
to generate PSD results.
To produce binary Raman images, the raw image data
were preprocessed using a median filter to remove isolated,
high intensity pixels characteristic of cosmic ray detection.
The data were then bias-corrected to minimize intensity
contributions resulting from background fluorescence and
detector thermal noise. Subsequently, the Raman image was
vector-normalized to minimize contributions from particle
surface topography and nonuniformity of response associated
with the Gaussian laser illumination profile. The API-specific
image at 1,662 cmj1 was extracted and Gaussian image noise
was reduced using a Wiener-filter noise reduction algorithm
(14) prior to applying brightfield image-guided binarization
thresholding of the image intensities. Particle size distribution in this study was based on particle chord lengths
(maximum distance across a particle).
Step 3. Demonstrate Raman chemical imaging PSD
analysis on a known formulation of aqueous nasal spray
suspension. In separate experiments, formulated samples
containing BDP with nominal particle sizes of 1.4, 2.2, 3.4
and 8.3 mm were sprayed onto microscope slides and allowed
to dry. For each sample, brightfield, polarized light and
Raman chemical images were obtained on identical fields of
view. Overlaying these images provided valuable insight into
the composition, location and association of particles. These
images were processed using ChemImage Xperti software
to obtain the PSD of the API particles as described above.
Step 4. Use RCI to measure API particle size in
aqueous nasal spray suspension formulations. Five formulated BDP samples whose PSDs were blinded to ChemImage
personnel and marked as 7E1, 8E1, 9E1, 10E1 and 11E1 were
provided by FDA personnel. Formulated samples were
characterized using the protocol detailed in Step 3. Sufficient
non-overlapping fields of view were examined such that at
least 100 API particles were counted for each formulation.
For single FOV results (such as size standards), particles
that crossed the perimeter of the FOV were manually
rejected from the particle size analysis. For multiple FOV
images (i.e., montages), all particles were included in the
analysis. A montage is a composite image comprised of an
X by Y grid of adjacent FOVs that preserve the spatial
arrangement of the sample on a larger spatial scale than any
single FOV.
Statistical Methods
Statistical analysis was conducted to compare the PSD of
the API (maximum chord, Raman) versus the PSD (maximum chord, Raman) of batch formulated with that API. For
the formulated products, data for all API particles were used,
including those that appeared to adhere to an excipient
particle. This is a circumstance where size measurements
based on imaging and those obtained from laser light
scattering will certainly differ. An API particle attached to
Raman Imaging of Aqueous Nasal Spray Suspensions
937
Fig. 1. Brightfield reflectance image (a), Raman chemical image (b) and brightfield/Raman image overlay
image (c) of a hexagonally close-packed arrangement of 10 mm, nominal) NIST-traceable polystyrene
microsphere size standards.
an excipient particle will appear only as a single large particle
in the LLS experiment but chemical imaging will allow those
particles to be differentiated. KolmogorovYSmirnov tests (15)
were performed to test for statistically significant differences
between two PSDs.
Regression analysis was performed on the mean PSD of
API Lots D, F, H and I determined by LLS and the mean
PSD of formulated product determined by Raman chemical
imaging. Similar analyses were performed on the median and
mode summary statistics. These analyses were performed on
both untransformed and log-transformed data.
RESULTS
Validation of Raman Chemical Imaging as a Particle
Sizing Method
A blinded particle size standard study was performed
using six polystyrene (PS) microsphere size standards in
order to determine the accuracy of sizing micron dimension
particles using RCI and optical microscopy. Initial efforts to
characterize isolated, single PS microspheres resulted in a
consistent overestimation of particle diameter for both
optical and Raman chemical imaging measurements. The
systematic overestimates were on the order of 43% for
optical imaging and 24% for Raman chemical imaging
relative to the particle diameter reported by the supplier.
The overestimation in size may be attributable to the
difficulty in determining the edge of the spherical particle,
especially when approaching the diffraction limit of light
(human error). To minimize systematic overestimation, we
prepared close packed hexagonal arrays of the microspheres.
The resulting particle size can be determined more accurately
by measuring multiple PS microspheres in a row and dividing
by the total number of spheres, which effectively minimizes
edge detection error. This method was used for all PS
microsphere studies that formed close-packed arrays.
Using the hexagonal array sizing method, the six
different PS standards were prepared by placing small drops
of each of the size standard suspensions on standard glass
microscope slides and allowing the suspension to dry. Brightfield and RCI measurements were made on particle size
standards that formed a hexagonal close-packing arrangement when deposited on a glass microscope slide. Mean
particle size and the associated standard deviation were
determined as described above. Fig. 1 shows a brightfield
reflectance image (a), Raman chemical image (b) and brightfield/Raman image overlay image (c) of a hexagonally closepacked arrangement of 10 mm (nominal) NIST-traceable PS
microsphere size standards.
Imaging results for the NIST-traceable particles are
shown in Table I. Raman chemical imaging-based sizing
results for size standards that formed a hexagonal closepacked arrangement are in good agreement with the nominal
NIST-traceable size standard values. A two-sided t test
(a=0.05) was performed to determine whether there was a
statistical difference between the population means for the
Raman measurements compared to the NIST-traceable
optical microscopy results. The t test results indicate that
there is no statistically significant difference between the
mean particle sizes determined by RCI and the NISTtraceable optical sizing method performed by the PS
Table I. Results of Polystyrene Particle Sizing Validation Experiment
NIST-traceable Value
(Duke Scientific) (mm)
0.71T0.01
1.0T0.01
2.1T0.02
5.1T0.5
10.0T0.6
32T2
Original Value: Brightfield Transmittance
(ChemImage) (mm)
0.98T0.02
1.9T0.2
3.5T0.1
6.7T1.0*
12.2T0.5
36T3
Original Value: Raman
(ChemImage) (mm)
0.9T0.2
1.4T0.2
2.5T0.4
6.3T0.5*
12.8T1.3
35T2
Array Method Value: Brightfield/Raman
Overlay (ChemImage) (mm)
0.71T0.01
1.1T0.01
2.1T0.01
5.0T0.03*
10.3T0.1
31T1
Values reported are mean T standard deviation.
* The 5.1 mm size standard did not form close-packed arrays. The mean of three linear subarrays containing two or three particles each is
reported.
Doub et al.
938
Dextrose
Arbitrary Intensity
Polysorbate 80
Microcrystalline Cellulose (MCC)
Carboxymethylcellulose Sodium (CMC)
Benzalkonium Chloride
Phenylethyl Alcohol
Beclomethasone Dipropionate (BDP)
500
1000
1500
2000
2500
3000
Raman Shift (cm-1)
Fig. 2. Overlaid dispersive Raman spectra of all active and inactive ingredients.
microsphere supplier. The validation results shown in Table I
are significant in that they demonstrate the feasibility of
Raman chemical imaging for quantitative particle sizing. The
5.1 mm NIST traceable size standard could not be sized using
the array method as it did not provide the necessary
hexagonally close-packed arrangement of PS microspheres.
Lack of formation of a close-packed arrangement may be due
to the presence of impurities in the sample analyzed although
this has not been examined. However, by measuring short
Bchains^ of two to three particles, an average diameter within
2% of the nominal size was obtained.
The overestimation of particle diameter observed here is
systematic and can be minimized through appropriate
selection of binary thresholding criteria. These criteria may
include edge detection based on the optical image where
contrast exists and/or based on signal to noise ratios
associated with each pixel (i.e., spectrum) in the Raman
image. The image analysis procedures refined in the PS
Fig. 3. Brightfield reflectance images (a, b, c) and brightfield/Raman overlay images (d, e, f) from
representative fields of view for Lots D, E and F, respectively.
Raman Imaging of Aqueous Nasal Spray Suspensions
939
Fig. 4. Raman chemical imaging PSD results of micronized drug based on maximum chord length for
Lots D, E and F, respectively.
microsphere array studies led to the use of the optical-image
guided protocol for establishing the binarization threshold
levels of the API-specific particle sizing data.
Raman Spectral Analysis of Pure Ingredients
Raman spectra were obtained for the API and all
excipients present in Beconase AQ nasal spray. Fig. 2 shows
the overlaid dispersive Raman spectra of all active and
inactive ingredients. These spectra clearly illustrate that each
component has a characteristic Raman spectrum that can be
used to discriminate between API and other ingredients in
the formulated sample. The BDP Raman spectral feature at
1,662 cmj1 was selected as the optimal marker to discriminate API from excipients. Other features, as well as the
entire spectrum, could have been exploited to generate APIspecific Raman image contrast. However, the 1,662 cmj1
feature provides adequate discrimination between API and
any of the excipients.
Raman Chemical Imaging of Neat Micronized
Drug Substance
Raman chemical imaging was performed on six lots of
neat micronized drug substance. Fig. 3 shows single field-ofview (FOV) brightfield reflectance images (aYc) and bright-
Fig. 5. Raman chemical imaging PSD results based on maximum chord length for Lots H, I and J,
respectively.
Doub et al.
940
Table II. Sizing Results Comparison of Micronized (Raman vs. Laser-Light Scattering (LLS)) and Formulated (Raman) API
Micronized API
API Lot
D
E
J
F
H
H (duplicate)
I
Formulated API
Particle Size (Max Chord, mm)
(RAMAN)
D50* (mm) (LLS)
Span (LLS)**
1.4
1.8
1.8
2.2
3.4
2.0
2.0
5.8
2.5
3.9
2.4
2.0
4.3
2.2
3.5
8.3
4.0
3.7 (SD=4.1, n=170)
(SD=2.5,
(SD=1.5,
(SD=2.1,
(SD=1.6,
(SD=2.2,
n=203)
n=136)
n=32)
n=154)
n=59)
Formulation Lot
10E1
NA
NA
11E1
7E1
8E1
9E1
Particle Size (Max Chord, mm)
(RAMAN)
2.7 (SD=3.1,
NA
NA
3.1 (SD=2.6,
1.5 (SD=2.8,
1.2 (SD=3.5,
1.8 (SD=7.0,
n=108)
n=124)
n=150)
n=136)
n=103)
SD is the standard deviation, n equals number of particles counted. Median particle size is reported to facilitate comparison between LLS
measurement results and imaging data.
NA Not applicable: no formulation was prepared using this API lot.
* Volume median diameter
** (D90jD10)/D50
field/Raman overlay images (dYf) of micronized BDP Lots D,
E and F, respectively. Fig. 4 shows the PSD results based on
maximum chord length for Lots D, E and F. Fig. 5 shows
PSD results based on maximum chord length for Lots H, I
and J. These data are summarized in Table II, column 4.
Raman Chemical Imaging of Aqueous Nasal Spray
Suspension Control Study
Raman chemical images were collected for a Beconase
AQ nasal spray sample. Fig. 6 shows a brightfield reflectance
optical image (a), a polarized light image (b) and a bright-
field/Raman overlay image (c) of the nasal spray sample for a
single region of interest. The green areas in the brightfield/
Raman image show the distribution of BDP with respect to
other components visible in the brightfield image. The
overlay image reveals what appears to be the aggregation of
BDP with one or more excipients in the nasal spray sample.
Imaging spectrometer Raman signals (d) displayed as colorcoded mean spectra are shown from several regions of
interest containing particles that exhibit birefringence. We
observed that API particles are birefringent. Some other
particles, not characterized by RCI, are also birefringent. The
Raman spectra clearly reveal the characteristic drug peak for
Fig. 6. Brightfield reflectance image (a), polarized light image (b), and brightfield/Raman overlay image
(c) of Beconase AQ nasal spray sample for a single region of interest with averaged imaging
spectrometer-generated Raman spectra, color-coded to match indicated regions in the polarized light
image (d).
Raman Imaging of Aqueous Nasal Spray Suspensions
941
Fig. 7. Brightfield reflectance image (a), polarized light image (b) and brightfield/Raman overlay image
(c) of placebo (no API) formulation, color-coded to match indicated regions in the Raman chemical
image (d).
the drug particles and the absence of the drug peak for other
birefringent and non-birefringent components in the sample.
As part of the control study, a negative-control (placebo)
sample, blinded to the analyst was evaluated. Results are
shown in Fig. 7. As would be expected, BDP particles were
not detected in the placebo control samples.
Formulated Aqueous Nasal Spray Suspension Blind Study
Five formulated BDP samples were supplied for analysis
(7E1Y11E1). Fig. 8 shows an example of a single brightfield
reflectance image montage out of the two montages collected
to characterize LotD/10E1 (a), a binary Raman chemical
image montage of the corresponding area (b) and a fused
brightfield/Raman chemical image montage of the corresponding area (c). The green pseudo-colored areas in the
brightfield/Raman image show the distribution of BDP
within the nasal spray excipient background particles. Pseudo-coloring (a virtual staining technique) is based on the
characteristic BDP Raman signature. The Raman chemical
image montage shown here is comprised of 30 FOVs totaling
958,710 Raman spectra collected at a rate of 35 spectra/s.
The histogram in Fig. 9 describes the particle size
distribution for the 108 particles characterized in the LotD/
10E1 formulation using RCI. The median drug particle size
was determined to be 2.7 mm (SD=3.1). This PSD result is
Fig. 8. Brightfield reflectance image montage (a), binary Raman chemical image montage (b) and
brightfield/Raman chemical image montage (c) revealing BDP distribution for the LotD/10E1
formulation.
Doub et al.
942
results suggest that PSDs differ substantially between the lots
of API used to formulate the product and the API from the
corresponding lots in the formulated product. API PSD
differences observed between pre- and post-formulation
samples are not attributable to detection of excipient
particles, as RCI exhibits high specificity for API. Regression
analyses were performed to examine the relationships
between summary statistics (mean, median, and mode) of
the four lots of API measured by both LLS and Raman
chemical imaging and the respective formulations measured
by Raman chemical imaging. Correlation coefficients ranged
from 0.07 to 0.85, which in general do not support the a priori
expectation that the relative particle size relationship would
remain constant.
Assessment of Agglomerated Particles
Fig. 9. Total number of particles and maximum chord length-based
PSD for the Lot D/10E1 formulation when considering all particles
that show as API in the Raman image.
representative of 86 FOVs totaling 2,756,250 Raman spectra.
The low particle density observed here is typical of that
observed for the sprayed nasal formulation (see, for example,
Fig. 6b or c).
Table II summarizes the size data for the neat BDP
determined by both LLS and Raman, and for the BDP in the
associated formulated aqueous nasal spray suspensions. A
priori, similar PSDs between the particle size of the lot of
API used to formulate the product and the spectroscopically
differentiated particle size of the drug in the formulation was
anticipated. KolmogorovYSmirnov tests revealed statistically
significant differences (p<0.0001) in PSDs for all comparisons
(API Lot F versus formulation 11E1; Lot H versus formulation 7E1; Lot H versus formulation 8E1; Lot I versus formulation 9E1) except Lot D versus formulation 10E1. These
Due to the high specificity and high spatial resolution
capabilities of RCI combined with optical microscopy, direct
measurement of the presence of agglomeration (i.e. the
cohesion of API and excipient) and the contribution of API
to agglomerated particles can be performed. Alternative
analytical methods for assessing API PSD do not have this
capability. Without an ability to assess the presence and
degree of API-excipient agglomeration API PSD is likely to
be overestimated. We anticipate that in order to assess in
vitro BE, it will be necessary to assess the PSD of dispersed
and agglomerated API particles, as well as the extent of
agglomeration in the nasal spray. For example, it is plausible
that micronized API will have reduced availability to nasal
sites of action if a significant fraction adheres to excipient or
other API particles.
In Fig. 10, API particles that adhere to excipient
particles (circled in yellow) are clearly visible when viewed
as the Raman/brightfield overlay (a) for the LotD/10E1
formulation. The median PSD of the API was determined
to be 2.7 mm (SD=3.0, n=100) for free API particles and 3.1 mm
Fig. 10. Binary Raman chemical image (a) and maximum chord length-based PSD histogram (b) of API
particles (green bar-free; yellow bar-adhered to excipient) that show as API when viewed as the Raman/
brightfield overlay for the LotD/10E1 formulation.
Raman Imaging of Aqueous Nasal Spray Suspensions
943
Table III. API Particle Association Sizing Results (median max chord, mm)
Formulation Lot
LotH/7E1
LotH/8E1
LotI/9E1
LotD/10E1
LotF/11E1
All Particles Containing API
1.5
1.2
1.8
2.7
3.1
(SD=2.8,
(SD=3.5,
(SD=7.0,
(SD=3.1,
(SD=2.6,
n=150)
n=136)
n=103)
n=108)
n=124)
Free API Particles
Adhered Particles
1.5
1.2
1.8
2.7
3.1
6.2
11.0
6.1
3.1
3.1
(SD=2.5,
(SD=3.3,
(SD=6.8,
(SD=3.0,
(SD=2.6,
n=143)
n=133)
n=96)
n=100)
n=105)
(SD=4.5,
(SD=1.0,
(SD=8.3,
(SD=4.3,
(SD=2.3,
n=7)
n=3)
n=7)
n=8)
n=19)
Values reported as median
SD Standard deviation
(SD=4.3, n=8) for adhered particles. Table III shows API
particle size data for formulated aqueous nasal spray suspensions in which we tabulate the median size of: (1) all particles
containing API; (2) API particles devoid of excipients; and (3)
API particles adhered to excipient particles. The larger
variance observed for adhered particles may reflect their more
irregular shape as compared to free API particles or it may be
a consequence of observing only a small number of adhered
particles. It should be noted that no optical evidence of API
adhering to other API particles is observed. However, this
does not preclude the possibility of API particles agglomerating and being detected as a single particle.
DISCUSSION
Raman Spectral Analysis of Pure Ingredients
Raman chemical imaging and spectroscopy has been
studied and used for pharmaceutical materials evaluation for
many years. The high degree of specificity provided by
Raman scattering is well-known (16), and is demonstrated
in Fig. 2 in which each component of the nasal spray
formulation has a unique Raman spectrum. The uniqueness
of the component Raman spectra provides the basis for the
underlying specificity of the Raman chemical images.
Validation of Raman Chemical Imaging as a Particle Sizing
Method
Using brightfield imaging to guide the thresholding of
the Raman chemical images, we have demonstrated the
feasibility of using widefield Raman chemical imaging for
particle size determination in the particle size range of
interest. Fig. 1 shows good agreement between the nonchemical-specific optical brightfield result and chemicalspecific Raman chemical imaging result. A two-sided t test
(a=0.05) evaluation of the data shown in Table I and other
size standards ranging between 0.71 and 31 mm (data not
shown) indicates that there is no statistically significant
difference between the mean particle sizes determined by
the array method (brightfield/Raman overlay) and the NISTtraceable sizes supplied by the particle manufacturer.
Raman Chemical Imaging of Neat Micronized Drug
Substance
The Raman chemical imaging PSD results from the neat
micronized drug substance compare favorably with particle
sizing results obtained using laser-light scattering (LLS) for
sample lots E, F, H, considering the differences in methodology. Lots D, I and J are less in agreement. The differences
observed between the Raman and laser scattering results may
be attributed to several causes. First, there are fundamental
differences in the mechanisms of the sizing methods. A
limitation of the laser scattering method is that the technique
assumes a spherical particle shape, while, as can be seen in
the optical images of the samples studied here, the particles
are often irregular in shape. It is well known that for particles
with high aspect ratio, laser scattering results are inherently
inaccurate (17,18). Moreover, laser scattering measurements
determine size based on a random particle orientation within
the sample. In contrast, Raman imaging evaluates a fixed
particle orientation deposited on a surface. The Raman
imaging measurements are likely to be dominated by
preferential particle alignment by which particles lie flat on
the substrate following deposition revealing the longest
dimension of the particle. Optical evidence observed to date
suggests particles do not preferentially align normal to the
substrate. Though this does not preclude the possibility, it is
not a dominant or even prevalent effect. The imbalance in
the number of counted particles between an ensemble
method such as LLS and the single-particle method used
here may also contribute to the apparent difference between
particle sizes. While laser light scattering methods fall into
the category of ensemble methods where the properties of
the entire distribution within the beam are measured, the
Raman microimaging measurements are representative of
single particle methods. In the present study, measurements
performed on the micronized drug were acquired on as few
as 32 particles per drug lot. These counts represent only a
small number of FOVs, thus the observed particle size
may not be fully representative of the API particles in the
sample.
Raman Chemical Imaging of Formulated Aqueous Nasal
Spray Suspension
Optical (i.e., brightfield) imaging is highly sensitive but
has low intrinsic chemical specificity for classifying API
particulate based solely on morphological factors (i.e.,
particle size and shape). Polarized light microscopy (PLM)
may be used to enhance nasal spray particle image contrast
and provide additional discrimination capabilities based on
the inherent birefringence of the materials. The birefringence
can be used for detection of anisotropic crystalline species.
However, PLM, like optical reflectance microscopy, is not
chemically-specific. As shown in Fig. 6b, API and multiple
Doub et al.
944
excipient particles exhibit varying degrees of birefringence
making it impractical to perform chemical identification
based on PLM. Both optical microscopy and PLM provide
good guidance for subsequent higher chemical specificity
detection methods, including RCI. RCI provides a sound
basis for discriminating nasal spray ingredients based on the
molecular chemical makeup of the individual components.
By overlaying brightfield and Raman images as shown in Fig.
6c, quantitative information on the API particle size and
degree of association of particles within the formulation can
be evaluated. For instance, in Fig. 6c the API adheres to one
or more excipients in the nasal spray sample and indicates
that RCI may provide a means to investigate changes that
may occur in the formulation as a result of the formation of
particle agglomerations. This type of information is not
obtainable by alternative particle sizing methods.
Formulated Aqueous Nasal Spray Suspension Blind Study
As part of the Nasal Spray Suspension Blind Study,
FDA sent ChemImage five lots of formulated material (7E1,
8E1, 9E1, 10E1 and 11E1). Lots 7E1 and 8E1 were
formulated from the same lot of API, but this fact was
blinded to ChemImage. Statistical comparison of the Raman
particle size results (Table II) for these two lots showed them
to be the same with a 95% confidence level. Median particle
size of the API in the nasal spray formulation determined by
RCI did not reveal a rank order relationship with micronized
API prior to formulation determined by either LLS or RCI.
However, differences between LSS and imaging results are
well known (19). Although differences arise primarily
because these methods provide different measures of particle
size, results from the present study suggest a need for further
development of standardized sample preparation prior to
chemical imaging. For example, for samples examined by
RCI, a collection of microscopic fields of view forming a
wedge from spray pattern center to outer edge could be
obtained. This would provide a truer representation of the
overall particle size distribution within the sample than is
obtained from the narrow region of the spray pattern
examined in this study. In addition, differences between
micronized and formulated API may be due in part to as yet
unknown formulation-induced changes. Considerable variability was observed in repeat RCI measurements of
micronized drug and formulated product (data not shown).
Statistical analyses based on the KolmogorovYSmirnov test
comparing particle size of free API versus API in product
also did not reveal a consistent pattern.
CONCLUSIONS
Raman chemical imaging has been evaluated as a
method for establishing chemical identity, particle size, and
particle size distribution (PSD) characteristics of a representative corticosteroid, BDP, in aqueous suspension of a nasal
spray formulation. PSD results collected on polystyrene
particle size standards show good statistical agreement
between the reported and the measured sizes determined
using Raman chemical imaging. Raman dispersive spectral
evaluation of corticosteroid nasal spray constituents indicates
that Raman spectroscopy has sufficient specificity to discriminate API from excipients, even in complex formulations.
Although it is well understood that LLS and imaging
provide different measures of size, our initial expectation was
that, given several Blots^ of API, rank order of particle size
would not be method dependent. However, rank order
correspondence was not observed in this study when particle
size was measured by the two methods (Table II). Reasons
for this may include differences in particle orientation
sensitivity between the two techniques and differences in
the number of particles measured by each method, i.e.,
ensemble versus single particle methods.
Results from analysis of formulated nasal sprays demonstrate the ability of RCI to identify the general shape of
API, as well as excipients, in situ within complex nasal spray
formulations recognizing some uncertainty of shape where
agglomeration occurs. By fusing brightfield optical imaging
and RCI, the technique also provides valuable insight into
the association of particles and has the potential to provide
unique information on API-excipient agglomeration.
While the goals of providing chemical differentiation,
particle size and particle size distribution in aqueous nasal
spray suspension products have not been fully realized, RCI
holds promise to provide this essential information. Inconsistency in measured particle sizes between micronized and
formulated API, along with high variability associated with
replicate measurements, is observed. Additional analytical
method development including sample preparation, increased
automation to enable measurement of a greater number of
particles, incorporation of more representative sampling, and
investigation of possible formulation-induced changes in
particle size are necessary for RCI to attain those goals.
ACKNOWLEDGEMENTS
We would like to thank Giancarlo De Servi (SICOR
S.p.A., Milan, Italy) for the gift of micronized BDP, FMC
BioPolymer (Newark, DE) for the gift of Avicel RC-591,
Joseph Vasiliou (Duke Scientific) for the recommendation to
use packed arrays to accurately estimate particle size of
polystyrene standard particles, and Qian H. Li, Mathematical
Statistician, FDA/CDER/Office of Biostatistics, for the
conduct of statistical analyses. We would also like to thank
the reviewers of this paper for their excellent comments.
REFERENCES
1. U.S. Department of Health and Human Services, Food and
Drug Administration, Center for Drug Evaluation and Research. April 2003, Draft Guidance for Industry, Bioavailability
and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays
for Local Action.
2. H. R. Morris, C. C. Hoyt, P. Miller, and P. J. Treado. Liquid
crystal tunable filter Raman chemical imaging. Appl. Spectrosc.
50:805Y811 (1996).
3. H.R. Morris, J F. Turner II, B. Munroe, R. A. Ryntz, and P. J.
Treado. Chemical imaging of Thermoplastic Olefin (TPO)
surface architecture. Langmuir 13:2961Y2972 (1999).
4. M. P. Nelson, C. T. Zugates, P. J. Treado, G. S. Casuccio, D. L.
Exline, and S. F. Schlaegle. Combining Raman chemical imaging
and scanning electron microscopy (SEM) to characterize ambient fine particulate matter. Aerosol Sci.Tech. 34:108Y117 (2001).
Raman Imaging of Aqueous Nasal Spray Suspensions
5. P. J. Treado, and M. P. Nelson. Raman imaging, handbook of
Raman spectroscopy. In I. R. Lewis and H. G. M. Edwards
(eds.), Marcel Dekker, Inc., New York, 2001, pp. 140Y159.
6. C. T. Zugates and P. J. Treado. Raman chemical imaging of
pharmaceutical content uniformity. [http://www.ijvs.com] Int. J.
Vibr. Spectrosc. 2:4 (1999).
7. L. C. Boogh, R. J. Meier, and H. H. Kausch. A Raman
microscopy study of stress transfer in high-performance expoxy
composites reinforced with polyethylene fibers. J. Polym. Sci., B,
Polym. Phys. 30:325Y333 (1992).
8. S. P. Nadula, T. M. Brown, R. W. Pitz, and P. A. DeBarber.
Single-pulse, simultaneous, multipoint, multispecies Raman
measurements in turbulent nonpremixed jet flames. Opt. Lett.
19:414Y416 (1994).
9. X. M. Yang, K. Ajito, D. A. Tryk, K. Hashimoto, and A.
Fujishima. Two-dimensional surface-enhanced Raman imaging
of a roughened silver electrode surface with adsorbed pyridine
and comparison with AFM images. J. Phys. Chem. 100:7293Y7297
(1996).
10. C. M. Stellman, K. S. Booksh, and M. L. Myrick. Multivariate
Raman imaging of simulated and BReal World^ glass-reinforced
composites. Appl. Spectrosc. 50:552Y557 (1996).
View publication stats
945
11. D. F. Steele, P. M. Young, R. Price, T. Smith, S. Edge, and D.
Lewis. The potential use of Raman mapping to investigate in
vitro deposition of combination pressurized metered-dose
inhalers. AAPS J.6:4 (2004).
12. M. Bowden, D. J. Gardiner, G. Rice, and D. L. Gerrand. Linescanned micro Raman spectroscopy using a cooled CCD
imaging detector. J. Raman Spectrosc. 21:37Y41 (1990).
13. N. L. Jestel, J. M. Shaver, and M. D. Morris. Hyperspectral
Raman line imaging of an aluminosilicate glass. Appl. Spectrosc.
52:64Y69 (1998).
14. J. Lim. Two-dimensional signal and image processing, PrenticeHall, Upper Saddle River, NJ, 1990.
15. W. W. Daniel. Applied Nonparametric Statistics, 2nd ed. PWSKENT Publishing Company, Boston, (1990), p. 330.
16. J. M. Chalmers and P. R. Griffiths (eds.), Handbook of
Vibrational Spectroscopy, Wiley, New York, 2002.
17. M. Levin. Particle characterizationVtools & methods. Lab.
Equip. 42(7):12Y14 (2005).
18. M. Levin. Sizing particles. Am. Lab. News 37(23):14Y15 (2005).
19. R. N. Kelly. False Assumptions: Laser Diffraction PSA Systems
Exposed. http://www.particlesize.com/Bibliography/false%20
with%20notes.pdf (Accessed 11/30/2006).